Stock comparison
IDEXX Laboratories
Medtronic
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
IDXX
IDEXX Laboratories
Market cap
$43.63B
Sector
Healthcare
MDT
Medtronic
Market cap
$100.34B
Sector
Healthcare
Overall winner
IDEXX Laboratories IDXX
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | IDXX | MDT | Winner |
|---|---|---|---|
| Warren Buffett | 75B | 58D | IDXX |
| Benjamin Graham | 80A | 63C | IDXX |
| Philip Fisher | 75B | 50C | IDXX |
| Peter Lynch | 71B | 55C | IDXX |
| Joel Greenblatt | 83C | 39D | IDXX |
| Charlie Munger | 87A | 51D | IDXX |
| Terry Smith | 84A | 52D | IDXX |
Side-by-side metrics
| Metric | IDXX | MDT |
|---|---|---|
| Market cap | $43.63B | $100.34B |
| P/E (TTM) | 39.0x | 21.2x |
| EV/EBIT | 31.6x | 20.9x |
| ROIC (TTM) | 40.66% | 6.43% |
| Gross margin | 62.05% | 61.95% |
| Net margin | 24.63% | 13.0% |
| Revenue CAGR 5y | 7.56% | 2.73% |
| EPS CAGR 5y | 10.79% | 7.88% |
| Debt / Equity | 0.7x | 0.6x |
| Dividend yield | 0.0% | 3.73% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
IDXX leads on
- ROIC (TTM)40.66%vs 6.43%+84%
- Revenue CAGR 5y7.56%vs 2.73%+64%
- Net margin24.63%vs 13.0%+47%
- EPS CAGR 5y10.79%vs 7.88%+27%
MDT leads on
- Dividend yield3.73%vs 0.0%+100%
- Market cap$100.34Bvs $43.63B+57%
- P/E (TTM)21.2xvs 39.0x+46%
- EV/EBIT20.9xvs 31.6x+34%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.